Summary of the Interview with Dr. Dani Castillo on Advanced Gastric Cancer Treatment
This text presents an interview with Dr. Dani Castillo regarding a meta-analysis examining the impact of metastatic sites and Lauren subtype on survival outcomes for patients with HER2-negative advanced gastric cancer receiving first-line PD-1 inhibitors combined with chemotherapy.
Key Takeaways:
* Heterogeneity of Gastric Cancer: Gastric cancer is highly heterogeneous, with different metastatic sites (liver, peritoneum, bone) and Lauren histological subtypes influencing treatment response.
* Chemotherapy + Immunotherapy as Standard: Chemotherapy plus immunotherapy is the current standard first-line treatment, showing improved outcomes over the past decade.
* Peritoneal Disease Challenge: the study found no significant difference in outcomes between patients with and without peritoneal disease when treated with chemo-immunotherapy. This suggests this subgroup may benefit from alternative or additional approaches.
* Liver Metastasis: Patients with liver metastasis do appear to benefit from the standard chemo-immunotherapy combination.
* Tailored Treatment is Crucial: The findings emphasize the need for tailored therapeutic strategies based on the specific characteristics of each patient’s cancer.
* Recommendations for Clinicians:
* referral to Specialized Centers: Patients with extensive peritoneal disease should be referred to high-level academic centers with multidisciplinary programs.
* Consider locoregional Treatments: explore locoregional treatments like HIPEC (hyperthermic intraperitoneal chemotherapy) in conjunction with systemic therapy for peritoneal disease.
* Explore Different Immunotherapies: Further research is needed to compare the efficacy of different PD-1 inhibitors (tislelizumab, pembrolizumab, nivolumab).
* Early Clinical Trial Enrollment: Encourage patients to participate in clinical trials.
* Prognosis & Patient Communication: Gastric cancer with immune disease has a poor prognosis,and clear communication with patients about treatment expectations is essential.
In essence,the interview highlights the complexity of treating advanced gastric cancer and the need to move beyond a “one-size-fits-all” approach to improve patient outcomes.
